
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cogstate Limited is a health information services business based in Australia. Cogstate shares (CGS) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Cogstate has a trailing 12-month revenue of around $23.7 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, Cogstate's share price has had significant positive movement.
Its last market close was $0.8, which is 40.63% up on its pre-crash value of $0.475 and 175.86% up on the lowest point reached during the March crash when the shares fell as low as $0.29.
If you had bought $1,000 worth of Cogstate shares at the start of February 2020, those shares would have been worth $682.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,882.35.
52-week range | $0.29 - $0.8 |
---|---|
50-day moving average | $0.6946 |
200-day moving average | $0.4957 |
Target price | $1.27 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.021 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.8 on 2020-10-22
1 week (2021-01-08) | -25.58% |
---|---|
1 month (2020-12-18) | -30.43% |
3 months (2020-10-16) | 1.91% |
6 months (2020-07-17) | 100.00% |
1 year (2020-01-17) | 63.27% |
---|---|
2 years (2019-01-17) | 32.34% |
3 years (2018-01-17) | -15.02% |
5 years (2016-01-15) | 46.79% |
Valuing Cogstate stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cogstate's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cogstate's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $407,333 (£231,811).
The EBITDA is a measure of a Cogstate's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $23.7 million |
---|---|
Gross profit TTM | $10.1 million |
Return on assets TTM | -3.96% |
Return on equity TTM | -10.03% |
Profit margin | -5.55% |
Book value | 0.095 |
Market capitalisation | $136 million |
TTM: trailing 12 months
We're not expecting Cogstate to pay a dividend over the next 12 months.
Cogstate's shares were split on 6 August 2008.
Over the last 12 months, Cogstate's shares have ranged in value from as little as $0.29 up to $0.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cogstate's is 0.6595. This would suggest that Cogstate's shares are less volatile than average (for this exchange).
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2020, it had participated in approximately 1,800 academic research studies in approximately 200 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.